Metabolic & Cardiometabolic
PCSK9 inhibition does not impair cognition
In plain terms: Are PCSK9 inhibitors safe for memory and thinking?
Part of: 💊 PCSK9 inhibitors
Yes, on the evidence so far. The worry that driving LDL cholesterol very low with PCSK9 inhibitors might harm the brain has not held up: dedicated trials tracking memory and cognition found no meaningful decline. Very low LDL from these drugs looks cognitively safe.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (11)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Zimerman 2025 (FOURIER-OLE) venue: NEJM Evid · NEJM Evid | RCT | supports | high | FOURIER-OLE cognitive substudy (~8 yr): sustained very low LDL with evolocumab showed no cognitive decline — extends EBBINGHAUS reassurance over years. |
| Giugliano 2017 · Lancet | RCT | supports | high | FOURIER safety analysis: even patients reaching LDL <0.5 mmol/L (<20 mg/dL) had no excess neurocognitive adverse events — tests the very-low-LDL concern. |
| Giugliano 2017 (EBBINGHAUS) venue: N Engl J Med · N Engl J Med | RCT | supports | high | EBBINGHAUS: prospective cognitive testing in 1,204 FOURIER patients found no evolocumab-vs-placebo difference on the primary executive-function endpoint. |
| Gencer 2020 · J Am Coll Cardiol | RCT | supports | high | FOURIER: adjudicated and self-reported cognitive events did not differ by evolocumab vs placebo; achieved LDL was not linked to cognitive events. |
| Hirsh Raccah 2021 · Int J Cardiol | meta-analysis | supports | high | Meta-analysis and meta-regression of RCTs found no significant increase in neurocognitive adverse events with PCSK9 inhibitors, independent of achieved LDL-C. |
| Benn 2017 · BMJ | observational | supports | high | Mendelian randomization: lifelong LDL-lowering PCSK9/HMGCR variants were NOT associated with higher Alzheimer's or Parkinson's risk — genetics against harm. |
| Harvey 2018 · Eur Heart J | meta-analysis | supports | high | Pooled 3,340 alirocumab patients across 14 RCTs: no evidence of neurocognitive adverse events, including at very low LDL — independent of evolocumab data. |
| Schwartz 2018 (ODYSSEY OUTCOMES) venue: N Engl J Med · N Engl J Med | RCT | supports | moderate | ODYSSEY OUTCOMES: in 18,924 patients, neurocognitive adverse events were rare and balanced between alirocumab and placebo despite very low achieved LDL. |
| Li 2022 · Heart | meta-analysis | supports | high | Systematic review/meta-analysis of PCSK9-inhibitor safety across RCTs found no significant increase in neurocognitive adverse events versus control. |
| Williams 2020 2020 · Ann Neurol | observational | supports | moderate | Mendelian randomization: PCSK9-mediated LDL lowering showed no adverse (if anything protective) link with Alzheimer's disease, corroborating trial safety. |
| Nordestgaard 2025 · Alzheimers Dement | observational | supports | high | Drug-target MR + meta-analysis (~1M people): genetically-proxied PCSK9 and other LDL-lowering targets were associated with LOWER dementia risk, not higher. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.